MétaCan
Menu
Back to cohort

CSF proteomics for predicting response to treatment in patients with primary and secondary central nervous system lymphoma.

2024· article· en· W4399480981 on OpenAlexaff
Hannah Wilding, Aastha Aastha, Nicholas Mikolajewicz, Leonardo de Macêdo Filho, Debarati Bhanja, Madison Heebner, Shahbaz Khan, Vladimir Ignatchenko, Ahmad Ozair, Manmeet S. Ahluwalia, Michael Glantz, Thomas Kislinger, Alireza Mansouri

Bibliographic record

VenueJournal of Clinical Oncology · 2024
Typearticle
Languageen
FieldMedicine
TopicCNS Lymphoma Diagnosis and Treatment
Canadian institutionsUniversity Health NetworkUniversity of Toronto
Fundersnot available
KeywordsMedicineProteomicsCentral nervous systemPrimary central nervous system lymphomaLymphomaPrimary (astronomy)OncologyInternal medicineBiology

Abstract

fetched live from OpenAlex

e19083 Background: Despite exquisite responses to initial therapy in patients with CNS lymphoma (CNSL), relapse is common and overall responses are disappointing compared to other non-CNS diffuse large B-cell lymphomas. Incorporation of multi-agent intraventricular chemotherapy (MAIVC) alongside systemic therapy is a novel strategy. To maximize MAIVC benefit, identification of minimally-invasive biomarkers for guiding patient management is necessary. This study sought to identify cerebrospinal fluid (CSF)-based proteomic predictive biomarkers for MAIVC treatment response at baseline and for longitudinal monitoring of tumor burden in CNSL. Methods: A retrospective study of patients with primary or secondary CNSL that were treated with MAIVC at Penn State Health (2015-2021) was conducted and reported following REMARK guidelines. Each MAIVC cycle was administered via Ommaya reservoir and included a 2-drug combination comprised of methotrexate, rituximab, cytarabine, etoposide, topotecan, gemcitabine, or thiotepa. Patient-matched CSF was sampled at pre- and post-therapeutic endpoints and profiled using shotgun proteomics. Patients were grouped by treatment response status. Early responders were defined as patients achieving malignant-cell-free CSF within 6 MAIVC cycles, whereas never responders were those patients that i) did not achieve malignant-cell-free CSF by endpoint or ii) required salvage surgery or radiation during MAIVC. Results: 59 patients were included (21 primary; 38 secondary CNSL) with a median age of 66 years (range 25-90) and median number of MAIVC cycles of 8 (range 2-23). Only 1 required Ommaya removal secondary to infection. A proteomic-based classifier, comprised of SGCE, LCP1 and AGRN, discriminated between early and never responders with AUROC of 0.95. Comparison of CSF at baseline (<3 cycles MAIVC) vs. post-treatment (>12 cycles MAIVC) identified H3F3A, YWHAE, LCP1, CA1 and GAPDH as tumor burden biomarkers. Conclusions: Here we developed a proteomic signature capable of predicting CNSL patient response to MAIVC, with potential to improve clinical decision making. Furthermore, the biomarkers associated with tumor burden represent important indicators of treatment response. Ongoing efforts are underway to evaluate these candidates in independent validation cohorts.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.035
GPT teacher head0.369
Teacher spread0.333 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicCNS Lymphoma Diagnosis and TreatmentFrench-language works237,207